Trial participant flow chart for COMET PCOS trial with participants randomized to continuous oral contraceptive pills (COCP), extended-release metformin (Metformin XR), or both (COCP + metformin XR).

Trial participant flow chart for COMET PCOS trial with participants randomized to continuous oral contraceptive pills (COCP), extended-release metformin (Metformin XR), or both (COCP + metformin XR).

<p>Trial participant flow chart for COMET PCOS trial with participants randomized to continuous oral contraceptive pills (COCP), extended-release metformin (Metformin XR), or both (COCP + metformin XR).</p>

Сохранить в:

Библиографические подробности
Главный автор:	Anuja Dokras (8679261) (author)
Другие авторы:	Christos Coutifaris (245252) (author), Alan T. Remaley (77852) (author), Nehal N. Mehta (4588483) (author), Martin P. Playford (3127800) (author), Allen R. Kunselman (12647707) (author), Christy C. Stetter (22806397) (author), William C. Dodson (3286893) (author), Richard S. Legro (8086748) (author)
Опубликовано:	2025
Предметы:	Medicine Pharmacology Biotechnology Cancer Infectious Diseases Computational Biology Mathematical Sciences not elsewhere classified Chemical Sciences not elsewhere classified main methodologic limitation fasting glucose levels ci [− 3 ci [− 264 body mass index ages ≥ 18 4 %) completed 000 mg ), ≥ 25 kg ≤ 48 kg ≤ 40 years statistically significant changes polycystic ovary syndrome combined hormonal contraceptives rotterdam criteria ). different treatment groups comparable across groups ci [− 0 − 71 [; xlink "> clinicaltrials using metformin alone study period whilst combined group dropped 01 ), bmi mc − 0 2 </ sup 01 ), xlink "> − 0 combined groups combined ). − 2 study period significant difference metabolic syndrome 5 years 49 kg 10 [; combined group black ). waist circumference treat analysis screening visit robust evidence primary outcome p </ metformin group mean change mean bmi mean age
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

Change in Secondary Outcomes from Baseline to End of Study Visits within each group and comparison between OCP, metformin, and combined groups.
по: Anuja Dokras (8679261)
Опубликовано: (2025)

Baseline demographic and clinical characteristics of participants.
по: Anuja Dokras (8679261)
Опубликовано: (2025)

Key safety measures including adverse events.
по: Anuja Dokras (8679261)
Опубликовано: (2025)

Change in prevalence of metabolic syndrome (MetS) and its components between baseline (pre) and end of study visits (post).
по: Anuja Dokras (8679261)
Опубликовано: (2025)

Metabolic syndrome and individual components at baseline and end of study.
по: Anuja Dokras (8679261)
Опубликовано: (2025)

Demographic characteristics of patients in the metformin and non-metformin groups.
по: Xiaowen Zhang (83669)
Опубликовано: (2025)

Comparison of pathological subtypes between the metformin and non-metformin groups.
по: Xiaowen Zhang (83669)
Опубликовано: (2025)

Comparison of tumor characteristics between the metformin and non-metformin groups.
по: Xiaowen Zhang (83669)
Опубликовано: (2025)

Comparison of lesions stages between the metformin and non-metformin groups.
по: Xiaowen Zhang (83669)
Опубликовано: (2025)

Comparison of Ki-67 status between the metformin and non-metformin groups.
по: Xiaowen Zhang (83669)
Опубликовано: (2025)

Predefined adverse events for stopping metformin.
по: Nguyet Minh Nguyen (7645700)
Опубликовано: (2025)

Ki-67 IHC (15% positivity) in metformin group (MIB-1 antibody, × 20).
по: Xiaowen Zhang (83669)
Опубликовано: (2025)

Ki-67 IHC (40% positivity) in non-metformin group (MIB-1 antibody, × 20).
по: Xiaowen Zhang (83669)
Опубликовано: (2025)

Validation of ultrasound assessments across BMI groups using same-day ultrasound and radiography.
по: JoJo Yiying Zou (22676490)
Опубликовано: (2025)

Intra-operator and inter-rater reliability of ultrasound assessments across different BMI groups (n = 165).
по: JoJo Yiying Zou (22676490)
Опубликовано: (2025)

Bland-Altman analysis of US and Cobb angles across BMI tertiles.
по: JoJo Yiying Zou (22676490)
Опубликовано: (2025)

Spinal ultrasound images of subjects (A&B&C) with different BMIs across two scans (1&2).
по: JoJo Yiying Zou (22676490)
Опубликовано: (2025)

Scoliosis assessment in this study: A) ultrasound scan using the Scolioscan® system; B) standard posteroanterior radiograph showing a Cobb angle of 25.6°; C) corresponding coronal ultrasound image showing a curvature angle of 26.9° using SP method.
по: JoJo Yiying Zou (22676490)
Опубликовано: (2025)

Effect of metformin and P. dioscoridis on anxiety and depressive like behaviors in letrozole-induced PCOS.. Data are represented by Means
по: Rasha Atta (21608582)
Опубликовано: (2025)

Additional file 5 of Metformin for the treatment of breast cancer: a scoping review of randomized clinical trials
по: Carolina Fumico Massuda Araujo (22105977)
Опубликовано: (2025)

Effect of metformin and <i>P. dioscoridis</i> on sex hormonal profile and brain dopamine level in letrozole-induced PCOS.
по: Rasha Atta (21608582)
Опубликовано: (2025)

Additional file 1 of Placental and cerebral circulation in fetuses of mothers with polycystic ovary syndrome and the effect of Metformin exposure
по: Emma Nordtvedt (21698059)
Опубликовано: (2025)

Distribution of cases and adverse events associated with metformin.
по: Mengsi Peng (12882734)
Опубликовано: (2025)

Effect of metformin and <i>P. dioscoridis</i> ethanolic extract on dopamine receptor 2, DOPA decarboxylase and MAO-A gene expressions in letrozole-induced PCOS.
по: Rasha Atta (21608582)
Опубликовано: (2025)

Flow chart of included study participants.
по: William W. Hundley (22258411)
Опубликовано: (2025)

Data Sheet 1_Prophylactic administration of metformin alleviates withdrawal symptoms associated with heroin.zip
по: Minghong Liu (645228)
Опубликовано: (2025)

Visual summary of metformin-associated ADRs in adolescents with T2D.
по: Mengsi Peng (12882734)
Опубликовано: (2025)

<b>Metformin Boosts Intestinal Lipid sensing via GIP to Suppress Feeding</b>
по: Rachel Kuah (21646034)
Опубликовано: (2025)

Association of BMI with primary and secondary outcomes after adjusting for age, sex, index of multiple deprivation (for the United Kingdom data), primary surgical indication and American Association of Anaesthesiologists (ASA) score.
по: Epaminondas Markos Valsamis (8194083)
Опубликовано: (2025)

BMI distribution of study population using World Health Organisation (WHO) categories.
по: Epaminondas Markos Valsamis (8194083)
Опубликовано: (2025)

Patient demographics by BMI missingness in the United Kingdom NJR data and Danish data.
по: Epaminondas Markos Valsamis (8194083)
Опубликовано: (2025)

Association of BMI with primary and secondary outcomes after adjusting for age, sex, index of multiple deprivation (for the United Kingdom data), primary surgical indication and American Association of Anaesthesiologists (ASA) score.
по: Epaminondas Markos Valsamis (8194083)
Опубликовано: (2025)

Table 1_The effects of liraglutide and metformin treatment on fracture healing in partially insulinopenic diabetic rats.docx
по: Banu Turhan (22008425)
Опубликовано: (2025)

Flow chart of the study participants.
по: Oscar F. C. van den Bosch (22184246)
Опубликовано: (2025)

Characteristics of adolescents with T2D cases reporting ADRs to metformin in FAERS.
по: Mengsi Peng (12882734)
Опубликовано: (2025)

Enrollment process for this study.
по: Xiaowen Zhang (83669)
Опубликовано: (2025)

Original data set.
по: Xiaowen Zhang (83669)
Опубликовано: (2025)

<b>Does adjuvant Metformin reduce Olanzapine-induced metabolic adverse effects in patients diagnosed with Schizophrenia</b>
по: Aquib Butt (22209990)
Опубликовано: (2025)

The efficacy of metformin in counteracting olanzapine-induced hyperprolactinemia: an open-label prospective study
по: Kah Kheng Goh (4983368)
Опубликовано: (2025)

Subcellular Imaging of Lipid Metabolic Changes Regulated by Anti-Aging Metformin
по: Sirasit Prayotamornkul (20284443)
Опубликовано: (2025)